Seth Cohen, MD
Hematology & Oncology · New York, NYNPI 1619950136
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $118, 7.4 times the $16 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 11 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$32
- E.r. Squibb & Sons, L.L.C.$28
- Beone Medicines USA, Inc.$20
- ADC Therapeutics America, Inc.$20
- Blueprint Medicines Corporation$19
- Exelixis Inc.$18
- plus $45 from 3 others
Across 1 payment — averaging $1457.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1K
What the payments were for
- Food & beverage$182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Beone Medicines USA, Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| GSK | 1 | $16 |
| Celltrion USA Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
How this compares
$182 in reported general payments places this provider in the 20th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 45 | $731,546 |
| LenvimaLenvatinib Mesylate | 17 | $418,105 |
| XareltoRivaroxaban | 16 | $14,435 |
| MyrbetriqMirabegron | 11 | $10,102 |
| EliquisApixaban | 14 | $9,001 |
| Exemestane | 49 | $5,518 |
| Enoxaparin Sodium | 18 | $3,414 |
| Prednisolone Acetate | 48 | $2,468 |
| Ondansetron Hcl | 56 | $1,292 |
| Prochlorperazine Maleate | 50 | $679 |
| Potassium Chloride | 16 | $570 |
| Dexamethasone | 30 | $540 |
| Gabapentin | 46 | $488 |
| Losartan Potassium | 70 | $442 |
| Anastrozole | 25 | $375 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.